Aridis Pharmaceuticals Inc


Prices are adjusted according to historical splits.

Aridis Pharmaceuticals Inc Stock Price


Today's Low:
Today's High:
Open Price:
52W Low:
52W High:
Prev. Close:

Company Statistics

Market Cap.:
$13.94 million
Book Value:
Revenue TTM:
$2.87 million
Operating Margin TTM:
Gross Profit TTM:
Profit Margin:
Return on Assets TTM:
Return on Equity TTM:

Company Profile

Aridis Pharmaceuticals Inc had its IPO on 2018-08-10 under the ticker symbol ARDS.

The company operates in the Healthcare sector and Biotechnology industry. Aridis Pharmaceuticals Inc has a staff strength of 34 employees.

Stock update

Shares of Aridis Pharmaceuticals Inc opened at $0.29 at the start of the last trading session i.e. 2023-06-02.

The stocks traded within a range of $0.24 - $0.3, and closed at $0.29.

This is a +3.5% increase from the previous day's closing price.

A total volume of 2,718,573 shares were traded at the close of the day’s session.

In the last one week, shares of Aridis Pharmaceuticals Inc have increased by +61%.

Aridis Pharmaceuticals Inc's Key Ratios

Aridis Pharmaceuticals Inc has a market cap of $13.94 million, indicating a price to book ratio of 5.3976 and a price to sales ratio of 7.3343.

In the last 12-months Aridis Pharmaceuticals Inc’s revenue was $2.87 million with a gross profit of $-35401000 and an EBITDA of $-30581000. The EBITDA ratio measures Aridis Pharmaceuticals Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Aridis Pharmaceuticals Inc’s operating margin was -1086.39% while its return on assets stood at -101.84% with a return of equity of 0%.

In Q3, Aridis Pharmaceuticals Inc’s quarterly earnings growth was a positive 0% while revenue growth was a negative 22.5%.

Aridis Pharmaceuticals Inc’s PE and PEG Ratio

Forward PE
Trailing PE

Its diluted EPS in the last 12-months stands at $-1.7 per share while it has a forward price to earnings multiple of 2.0606 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Aridis Pharmaceuticals Inc’s profitability.

Aridis Pharmaceuticals Inc stock is trading at a EV to sales ratio of 17.5708 and a EV to EBITDA ratio of -1.2481. Its price to sales ratio in the trailing 12-months stood at 7.3343.

Aridis Pharmaceuticals Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$12.12 million
Total Liabilities
$42.28 million
Operating Cash Flow
Capital Expenditure
Dividend Payout Ratio

Aridis Pharmaceuticals Inc ended 2023 with $12.12 million in total assets and $0 in total liabilities. Its intangible assets were valued at $12.12 million while shareholder equity stood at $-35823000.00.

Aridis Pharmaceuticals Inc ended 2023 with $78000.00 in deferred long-term liabilities, $42.28 million in other current liabilities, 2000.00 in common stock, $-189279000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $1.89 million and cash and short-term investments were $1.89 million. The company’s total short-term debt was $9,152,000 while long-term debt stood at $3.50 million.

Aridis Pharmaceuticals Inc’s total current assets stands at $8.64 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $248000.00 compared to accounts payable of $4.23 million and inventory worth $0.

In 2023, Aridis Pharmaceuticals Inc's operating cash flow was $0 while its capital expenditure stood at $0.

Comparatively, Aridis Pharmaceuticals Inc paid $0 in dividends in 2023.

Other key metrics

Current Trading Price
52-Week High
52-Week Low
Analyst Target Price

Aridis Pharmaceuticals Inc stock is currently trading at $0.29 per share. It touched a 52-week high of $2.77 and a 52-week low of $2.77. Analysts tracking the stock have a 12-month average target price of $6.

Its 50-day moving average was $0.24 and 200-day moving average was $0.81 The short ratio stood at 0.29 indicating a short percent outstanding of 0%.

Around 4026.2% of the company’s stock are held by insiders while 1988.2% are held by institutions.

Frequently Asked Questions About Aridis Pharmaceuticals Inc

The stock symbol (also called stock or share ticker) of Aridis Pharmaceuticals Inc is ARDS

The IPO of Aridis Pharmaceuticals Inc took place on 2018-08-10

Similar Industry Stocks (Biotechnology)

Last Price
Jfrog Ltd (FROG)
Safran SA (SAFRY)
InflaRx N.V. (IFRX)
Sunrun Inc (RUN)
Oswal Greentech Ltd (BINDALAGRO)

Most Active

Last Price
Zomato Limited (ZOMATO)
Tesla Inc (TSLA)
Yes Bank Limited (YESBANK)

Top Gainers

Last Price
AEye Inc (LIDRW)

Top Losers

Last Price


Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, focuses on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that is in Phase III pivotal trials for the treatment of lung infections resulting from S. aureus alphatoxin. The company is also developing AR-320 is a fully human IgG1 monoclonal antibody targeting S. aureus alpha toxin to treat infections caused by methicillin-resistant Staphylococcus aureus and methicillin-susceptible S. aureus; AR-105, a fully human IgG1 mAb, which is in Phase II trials to target gram-negative bacteria P. aeruginosa; AR-101, a human IgM mAb, which is in Phase IIa clinical trials for the treatment of hospital-acquired pneumonia (HAP)and ventilator-associated pneumonia (VAP) caused by P. aeruginosa serotype O11; AR-401 that is in preclinical stage to treat infections caused by Acinetobacter baumannii; AR-201, a fully human IgG1 mAb preclinical program for respiratory syncytial virus; and AR-501, an anti-infective therapy, which is in Phase I/IIa clinical trial to manage chronic lung infections in cystic fibrosis patients. In addition, it is developing AR-712 and AR-701, a cocktail of two fully human immunoglobulin 1, or IgG1, mAbs, which is in Phase I/II clinical for the treatment of mild to moderate non-hospitalized COVID-19 patients. Aridis Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Los Gatos, California.


983 University Avenue, Los Gatos, CA, United States, 95032